Reply to comment on "Ultrasonographic scores for ileal Crohn's disease assessment: better, worse or the same as contrast‑enhanced ultrasound?
Journal
BMC gastroenterology
ISSN: 1471-230X
Titre abrégé: BMC Gastroenterol
Pays: England
ID NLM: 100968547
Informations de publication
Date de publication:
05 Aug 2023
05 Aug 2023
Historique:
received:
14
04
2023
accepted:
11
07
2023
medline:
7
8
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
We read the comments by Nylund K et al. regarding our paper "Ultrasonographic scores for ileal Crohn's disease assessment: Better, worse or the same as contrast‑enhanced ultrasound?". Intestinal ultrasound has become one of the most valuable developments in the past decade, a non-invasive, well-tolerated exam, with an easy repeatability, and absence of sedation, ionizing radiation, or preparation. Particularly for inflammatory bowel disease, where there is a lack of agreement of patient's symptoms with disease activity, in an era where the paradigm of mucosal healing is changing to transmural healing, and with the emergence of several therapies leading to repeated imaging surveillance, it is essential to highlight the role of intestinal ultrasound. Although intestinal ultrasound is an increasingly used tool to monitor inflammatory bowel disease activity, there is no widely accepted reproducible activity index, since the methodology for the development of the scores was shown to be insufficient in most studies and none have been adequately validated (Bots et al., J Crohns Colitis 12:920-9, 2018). In our study, we showed that the contrast-enhanced ultrasound (CEUS) peak enhancement derived from the time-intensity curve (TIC) is a promising non-invasive emerging method with a good accuracy to correlate clinical and endoscopic activity in the terminal ileum, superior to intestinal ultrasound scores relying on bowel wall thickness and colour Doppler.
Identifiants
pubmed: 37542209
doi: 10.1186/s12876-023-02883-4
pii: 10.1186/s12876-023-02883-4
pmc: PMC10403834
doi:
Substances chimiques
Contrast Media
0
Types de publication
Letter
Langues
eng
Sous-ensembles de citation
IM
Pagination
266Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Nylund K, Novak K, Wilkens R. Matters arising: comment on “Ultrasonographic scores for ileal Crohn’s disease assessment: better, worse or the same as contrast‑enhanced ultrasound?”. BMC Gastroenterol 23: https://doi.org/10.1186/s12876-023-02882-5 .
Sævik F, Eriksen R, Eide GE, Gilja OH, Nylund K. Development and validation of a simple ultrasound activity score for Crohn’s disease. J Crohns Colitis. 2021;15(1):115–24.
doi: 10.1093/ecco-jcc/jjaa112
pubmed: 32504533
Novak KL, Nylund K, Maaser C, Petersen F, Kucharzik T, Lu C, et al. Expert consensus on optimal acquisition and development of the International Bowel Ultrasound Segmental Activity Score [IBUS-SAS]: a reliability and inter-rater variability study on intestinal ultrasonography in Crohn’s disease. J Crohns Colitis. 2021;15(4):609–16.
doi: 10.1093/ecco-jcc/jjaa216
pubmed: 33098642
Klenske E, Bojarski C, Waldner M, Rath T, Neurath MF, Atreya R. Targeting mucosal healing in Crohn’s disease: what the clinician needs to know. Therap Adv Gastroenterol. 2019;12:1756284819856865.
doi: 10.1177/1756284819856865
pubmed: 31236140
pmcid: 6572879
Ripollés T, Martínez MJ, Paredes JM, Blanc E, Flors L, Delgado F. Crohn disease: correlation of findings at contrast-enhanced US with severity at endoscopy. Radiology. 2009;253(1):241–8.
doi: 10.1148/radiol.2531082269
pubmed: 19635834
Moskovitz DN, Daperno M, Van Assche GA, Baert F, Gevers A, Sostegni R, et al. Defining and validating cut-offs for the simple endoscopic score for Crohn’s disease. Gastroenterology. 2007;132(4):A173-A.
Sipponen T, Nuutinen H, Turunen U, Färkkilä M. Endoscopic evaluation of Crohn’s disease activity: comparison of the CDEIS and the SES-CD. Inflamm Bowel Dis. 2010;16(12):2131–6.
doi: 10.1002/ibd.21300
pubmed: 20848462
af Björkesten CG, Nieminen U, Turunen U, Arkkila P, Sipponen T, Färkkilä M. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn’s disease. Scand J Gastroenterol. 2012;47(5):528–37.
doi: 10.3109/00365521.2012.660542
pubmed: 22356594
Algaba A, Linares PM, Fernández-Contreras ME, Ordoñez A, Trápaga J, Guerra I, et al. Relationship between levels of angiogenic and lymphangi- ogenic factors and the endoscopic, histological and clinical activity, and acute-phase reactants in patients with inflammatory bowel disease. J Crohns Colitis. 2013;7(11):e569–79.
doi: 10.1016/j.crohns.2013.04.005
pubmed: 23642997
Serafin Z, Białecki M, Białecka A, Sconfienza LM, Kłopocka M. Contrast- enhanced ultrasound for detection of Crohn’s disease activity: systematic review and meta-analysis. J Crohns Colitis. 2016;10(3):354–62.
doi: 10.1093/ecco-jcc/jjv196
pubmed: 26507861